Galectin-9, a Player in Cytokine Release Syndrome and a Surrogate Diagnostic Biomarker in SARS-CoV-2 Infection
Najmeh Bozorgmehr, Siavash Mashhouri, Eliana Perez Rosero, Lai Xu, Shima Shahbaz, Wendy Sligl, Mohammed Osman, Demetrios J. Kutsogiannis, Erika MacIntyre, Conar O’Neil, Shokrollah Elahi
Abstract
Our results propose Gal-9 as an important contributing factor in cytokine release syndrome; therefore, Gal-9 inhibition may serve as a beneficial therapeutic approach by suppressing the hyperimmune activation in COVID-19 patients.
Topics & Concepts
OutbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)BiomarkerCytokineMedicine2019-20 coronavirus outbreakCytokine release syndromeImmunologyCytokine stormVirologyDiseaseBiologyPathologyInfectious disease (medical specialty)BiochemistryGalectins and Cancer BiologyOmental and Epiploic ConditionsCongenital Diaphragmatic Hernia Studies